Last reviewed · How we verify
C1 inhibitor (human) [C1 INH]
C1 inhibitor (human) is a plasma protein that regulates the initial step of the classical complement cascade by inhibiting C1s protease activity.
C1 inhibitor (human) is a plasma protein that regulates the initial step of the classical complement cascade by inhibiting C1s protease activity. Used for Hereditary angioedema (HAE) — acute attack treatment, Hereditary angioedema (HAE) — prophylaxis of recurrent attacks.
At a glance
| Generic name | C1 inhibitor (human) [C1 INH] |
|---|---|
| Also known as | CINRYZE, C1 esterase inhibitor (human) |
| Sponsor | Shire |
| Drug class | Complement inhibitor / Serine protease inhibitor |
| Target | C1s protease / Classical complement pathway |
| Modality | Biologic |
| Therapeutic area | Immunology / Rare disease |
| Phase | FDA-approved |
Mechanism of action
C1 INH is a serine protease inhibitor that controls activation of the complement system's classical pathway by binding to and inactivating C1s. By suppressing this early cascade step, it prevents excessive generation of inflammatory mediators (C3a, C5a) and bradykinin, thereby reducing pathological inflammation and angioedema. This mechanism is particularly relevant in hereditary angioedema (HAE), where C1 INH deficiency or dysfunction leads to uncontrolled complement and contact system activation.
Approved indications
- Hereditary angioedema (HAE) — acute attack treatment
- Hereditary angioedema (HAE) — prophylaxis of recurrent attacks
Common side effects
- Thrombosis / Thromboembolic events
- Headache
- Nausea
- Injection site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C1 inhibitor (human) [C1 INH] CI brief — competitive landscape report
- C1 inhibitor (human) [C1 INH] updates RSS · CI watch RSS
- Shire portfolio CI